UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The quantum leap in therapeutics for advanced ALK+ non-small cell lung cancer and pursuit to cure with precision medicine

Frontiers in oncology, 2022-08, Vol.12, p.959637-959637

2022

Volltextzugriff (PDF)

Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers

International journal of molecular sciences, 2020-02, Vol.21 (4), p.1416

2020

Volltextzugriff (PDF)

Experiencing the SARS-CoV-2 Pandemic Whilst Living With Cancer

Qualitative health research, 2022-02, Vol.32 (3), p.426-439

2022

Volltextzugriff (PDF)

A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma

Therapeutic drug monitoring, 2024-06, Vol.46 (3), p.332

2024

Volltextzugriff (PDF)

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211019675-17588359211019675

2021

Volltextzugriff (PDF)

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer

Clinical lung cancer, 2021-11, Vol.22 (6), p.e859-e869

2021

Volltextzugriff (PDF)

Hope in the era of precision oncology: a qualitative study of informal caregivers’ experiences

BMJ open, 2023-05, Vol.13 (5), p.e065753-e065753

2023

Volltextzugriff (PDF)

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis

International journal of molecular sciences, 2024-04, Vol.25 (7), p.3992

2024

Volltextzugriff (PDF)

Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study

European journal of surgical oncology, 2019-02, Vol.45 (2), p.218-224

2019

Volltextzugriff (PDF)

Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations

Cancer reports, 2024-08, Vol.7 (8), p.e2164-n/a

2024

Volltextzugriff (PDF)

The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as Biomarkers in Resected Pancreatic Cancer

Journal of clinical medicine, 2023-03, Vol.12 (5), p.1989

2023

Volltextzugriff (PDF)

Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy

Frontiers in oncology, 2020-03, Vol.10, p.237-237

2020

Volltextzugriff (PDF)

First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study

Frontiers in oncology, 2024, Vol.14, p.1305720-1305720

2024

Volltextzugriff (PDF)

Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma

Pancreas, 2020-02, Vol.49 (2), p.224-229

2020

Volltextzugriff (PDF)

The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer

Cancers, 2022-07, Vol.14 (15), p.3620

2022

Volltextzugriff (PDF)

Living (well) with cancer in the precision era

SSM. Qualitative research in health, 2022-12, Vol.2, p.100096, Article 100096

2022

Volltextzugriff (PDF)

Life-threatening diarrhea in neuroendocrine tumors: two case reports

Journal of medical case reports, 2021-10, Vol.15 (1), p.1-542, Article 542

2021

Volltextzugriff (PDF)

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis

Biomedicines, 2023-06, Vol.11 (7), p.1827

2023

Volltextzugriff (PDF)

Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis

Journal of clinical medicine, 2021-06, Vol.10 (12), p.2700

2021

Volltextzugriff (PDF)

ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance

JTO clinical and research reports, 2024-09, Vol.5 (9), p.100703, Article 100703

2024

Volltextzugriff (PDF)

LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC

JTO clinical and research reports, 2023-04, Vol.4 (4), p.100490-100490, Article 100490

2023

Volltextzugriff (PDF)

Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease

JCO precision oncology, 2021-11, Vol.5 (5), p.561-568

2021

Volltextzugriff (PDF)

A sociology of precision‐in‐practice: The affective and temporal complexities of everyday clinical care

Sociology of health & illness, 2021-11, Vol.43 (9), p.2178-2195

2021

Volltextzugriff (PDF)

Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?—the shifting paradigm of therapeutics

Translational lung cancer research, 2018-02, Vol.7 (S1), p.S39-S45

2018

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(48)

Sprache

Englisch
(48)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(38)
Oncology
(25)
Humans
(20)
Aged
(12)
Female
(12)
Male
(12)
Non-Small Cell Lung Cancer
(12)
Chemotherapy
(11)
Australia
(10)
Adult
(9)
Lung Cancer
(9)
Lung Neoplasms - Drug Therapy
(9)
Middle Aged
(9)
Aged, 80 And Over
(8)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(8)
Carcinoma, Non-Small-Cell Lung - Genetics
(8)
Immunotherapy
(8)
Lung Neoplasms - Genetics
(8)
Metastasis
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The quantum leap in therapeutics for advanced ALK+ non-small cell lung cancer and pursuit to cure with precision medicine

Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers

Experiencing the SARS-CoV-2 Pandemic Whilst Living With Cancer

A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial)

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer

Hope in the era of precision oncology: a qualitative study of informal caregivers’ experiences

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis

Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study

Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations

The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as Biomarkers in Resected Pancreatic Cancer

Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy

First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study

Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma

The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer

Living (well) with cancer in the precision era

Life-threatening diarrhea in neuroendocrine tumors: two case reports

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis

Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis

ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance

LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC

Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease

A sociology of precision‐in‐practice: The affective and temporal complexities of everyday clinical care

Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?—the shifting paradigm of therapeutics

Suchergebnisse filtern